Quantcast

Latest Acute coronary syndrome Stories

2014-08-04 12:31:19

LONDON, Aug. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_acute_coronary_syndrome_acs_epidemiology_forecast_2022.html EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare...

2014-07-29 16:27:56

BASKING RIDGE, N.J., July 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights....

2014-07-14 23:02:45

ReportsnReports.com adds “EpiCast Report Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022” to its store. The majority of the cases occurred in men (58.15%) and in those ages 65 years (69.34%). Dallas, TX (PRWEB) July 14, 2014 Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will...

2014-07-02 20:21:45

BASKING RIDGE, N.J., July 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that the Data Safety Monitoring Board (DSMB) has initiated an unplanned review of data from the REGULATE-PCI trial. Patient enrollment has been paused until the DSMB has completed its...

2014-05-21 12:26:28

Branded Products That Improve Hospital-Based Outcomes Have Advantages in Securing Preferred Drug Status in ACOs, According to Findings from Decision Resources Group BURLINGTON, Mass., May 21, 2014 /PRNewswire/ -- Decision Resources Group finds that managed care organizations and cardiologists alike believe accountable care organizations (ACOs) will reduce costs and improve outcomes for acute coronary syndrome (ACS) and atrial fibrillation (AF). A survey of 100 non-interventional cardiologists...

2014-05-14 08:30:11

Conference Call and Webcast, May 14, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J., May 14, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results...

2014-05-07 08:32:21

BASKING RIDGE, N.J., May 7, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Wednesday, May 14, 2014, at 8:30 a.m. EDT to discuss its first quarter 2014 financial results and corporate highlights. Interested participants and investors may...

2014-04-02 20:22:41

REGULATE-PCI Opened to "All Comers" PCI Population BASKING RIDGE, N.J., April 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the...

2014-03-10 08:29:26

Enrollment in the Phase 3 REGULATE-PCI Trial is Ongoing for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention BASKING RIDGE, N.J., March 10, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary...

2014-02-20 08:30:13

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use SummaryGBI Research has released its pharmaceutical research,...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related